NASDAQ · TLPH
Healthcare · Drug Manufacturers - Specialty & Generic
$1.24
Up+$0.00 (+0.00%)
Updated Sep 14, 2026, 10:19 AM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 19 trading sessions · Daily adjusted prices
TLPH closed at $1.24 after 19 trading sessions, up 3.33% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $1.24 | $1.26 | $1.23 | $1.24 | 151.34K |
| Sep 10, 2026 | $1.2001 | $1.245 | $1.19 | $1.24 | 217.15K |
| Sep 9, 2026 | $1.20 | $1.23 | $1.19 | $1.22 | 62.91K |
| Sep 8, 2026 | $1.19 | $1.2184 | $1.19 | $1.19 | 151.37K |
| Sep 4, 2026 | $1.20 | $1.21 | $1.195 | $1.20 | 59.87K |
| Sep 3, 2026 | $1.21 | $1.21 | $1.19 | $1.20 | 64.8K |
| Sep 2, 2026 | $1.17 | $1.20 | $1.17 | $1.20 | 139.07K |
| Sep 1, 2026 | $1.19 | $1.1999 | $1.18 | $1.18 | 63.91K |
| Aug 31, 2026 | $1.20 | $1.20 | $1.19 | $1.19 | 44.54K |
| Aug 28, 2026 | $1.23 | $1.23 | $1.20 | $1.20 | 123.93K |
| Aug 27, 2026 | $1.26 | $1.28 | $1.22 | $1.23 | 145.44K |
| Aug 26, 2026 | $1.23 | $1.27 | $1.21 | $1.26 | 206.6K |
| Aug 25, 2026 | $1.21 | $1.25 | $1.18 | $1.23 | 318.66K |
| Aug 24, 2026 | $1.19 | $1.2199 | $1.18 | $1.19 | 86.64K |
| Aug 21, 2026 | $1.19 | $1.215 | $1.17 | $1.19 | 109.54K |
| Aug 20, 2026 | $1.19 | $1.205 | $1.175 | $1.19 | 217.48K |
| Aug 19, 2026 | $1.21 | $1.23 | $1.18 | $1.19 | 558.76K |
| Aug 18, 2026 | $1.19 | $1.24 | $1.185 | $1.21 | 425.25K |
| Aug 17, 2026 | $1.24 | $1.27 | $1.18 | $1.20 | 346.98K |
The latest Smart Investors Daily articles mentioning TLPH.
TLPH research
Company profile and research snapshot.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 30, 2026 | WestPark Capital | Buy | — |
| Apr 1, 2025 | HC Wainwright & Co. | Buy | — |
| Jan 21, 2025 | HC Wainwright & Co. | Buy | — |
| Aug 16, 2024 | HC Wainwright & Co. | Buy | — |
| May 15, 2024 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 3, 2026
Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that Company management will be presenting at the H.C. Wainwright 28th Annual Global Investment Conference.
SeekingAlpha · Aug 13, 2026
Talphera, Inc. (TLPH) Q2 2026 Earnings Call August 12, 2026 4:30 PM EDTCompany ParticipantsRaffi Asadorian - Chief Financial OfficerVincent Angotti - CEO...
Benzinga · Aug 12, 2026
Talphera (NASDAQ:TLPH) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.07) by 14.29 percent. This is a 40 percent increase over losses of $(0.10) per share from the same
Yahoo · Aug 5, 2026
Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will host a conference call and webcast on Wednesday, August 12, 2026 at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss financial results for the second quarter ended June 30, 2026 and recent business progress.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning TLPH.
